Inflammation and Thrombotic Disorder
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (1 September 2019) | Viewed by 204
Special Issue Editor
Special Issue Information
Dear Colleagues,
While thrombosis has been considered the center of vascular events, recent evidence suggests that inflammation is a driver of human diseases, including cardiovascular conditions. Today, it is known that, independent of lipid levels, the NOD-like receptor protein 3 (NLRP3) inflammasome activates interleukin-1β and promotes focal development of atherosclerosis within arteries. The specific targeting of interleukin-1β as a cytokine-based therapy for the secondary prevention of atherosclerotic events was successful in the CANTOS trial, lending support to the role of this inflammatory pathway in atherosclerosis. The proinflammatory cytokine interleukin-1β plays multiple roles in the development of atherothrombotic plaques, including the induction of procoagulant activity, the promotion of monocyte and leukocyte adhesion to vascular endothelial cells and the growth of vascular smooth muscle cells. It is promoted by cholesterol crystals, neutrophil extracellular traps, tissue hypoxia and arterial flow patterns that are known to promote the focal development of atherosclerosis within arteries. However, whether the NLRP3-phenotype also drives other aspects of cardiovascular disease, e.g., venous thromboembolism, obesity-associated heart failure, cancer-associated thrombosis and age-related vascular stiffening is unknown. In this issue of Cells (Inflammation and Thrombotic Disorders), experts in the fields will review the inflammatory barcodes that have been documented in association with subsets of cardiovascular disease.
Prof. Irene Marthe Lang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammation
- thrombosis
- cardiovascular disease
- ageing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
